Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
126,115
datasets available to search
ShareScore release 0.9.0
Dataset results
126,115 results for “Patients”
Performance of Advanced Ambu Bag System among Adult Patients with Mechanical Ventilation: A Mixed-Effects Analysis
<p>We conducted the study at the Department of Stroke Care of the Can Tho Central General Hospital, Vietnam. There are eight intensive care beds for critical illness. The study was performed according to the Helsinki Declaration and approved by the Can Tho Central General Hospital ethics committee. All patients gave written informed consent by a legal surrogate. We enrolled patients with mechanical ventilation between November 2022 and September 2023. The inclusion criteria were: (1) patients aged 16 years and older, (2) pulse rate less than 120 times per minute, (3) systolic blood pressure from 110 to 160 mmHg, (4) peripheral oxygen saturation (SpO<sub>2</sub>) greater than 90%, (5) spontaneous breathing rate less than 28 times per minute, (6) end-tidal carbon dioxide (EtCO<sub>2</sub>) from 20 to 45 mmHg, (7) secretion required suction less than one time per hour, (8) positive end-expiratory pressure less than or equal to 5 cmH<sub>2</sub>O, (9) fraction of inspired oxygen less than or equal to 60%, (10) minute ventilation less than 15 liters per minute, (11) diameter of a tracheal or tracheostomy tube greater than or equal to 7.0 mm, (12) no usage of sedation, (13) normal ST wave in the electrocardiogram. Patients were excluded from the trial if they had one of the following conditions: (1) acute myocardial infarction, (2) acute pulmonary embolism, or (3) new dangerous arrhythmias appeared in this episode (multiform ventricular ectopy, bigeminy or trigeminy ventricular ectopy, coupled ventricular ectopy, R-on-T ventricular ectopy, high-grade atrioventricular heart block, supraventricular tachycardia, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation), (4) using vasopressors or inotropic agents. Patients could withdraw from the study at any time without giving any reason. Besides, the patient stopped the trial of the advanced Ambu bag system immediately when one of the signs appeared, such as (1) the peripheral oxygen saturation lower than 90% prolonging more than 1 minute, (2) the end-tidal carbon dioxide greater than 45 mmHg or less than 15 mmHg prolonging more than 10 minutes, (3) pulse rate greater than 120 times per minute or less than 60 times per minute prolonging more than 10 minutes, (4) systolic blood pressure greater than 170 mmHg prolonging more than 10 minutes, (5) appearing dangerous arrhythmias, (6) progressive cognitive impairment (based on Grady coma scale), or (7) any abnormal sign that the physician evaluated the patient required respiratory support immediately with conventional mechanical ventilation.</p> <p> The following is the meaning of the variables in the study:</p> <p>age: Age of study participants.</p> <p>gender: Gender of study participants (0: Woman, 1: Man).</p> <p>day1: Day of admission to the hospital</p> <p>day2: Intervention day.</p> <p>dia1: Major disease.</p> <p>dia2: Cause of respiratory failure.</p> <p>nihss1: National Institute of Health Stroke Scale on admission</p> <p>hsg: Severity of cerebral hemorrhage (0: No hemorrhagic stroke, hi1: Scattered small petechiae, no mass effect, hi2: Confluent petechiae, no mass effect, ph1: Hematoma within infarcted tissue, occupying <30%, no substantive mass effect, ph2: Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect, 3a: Parenchymal hematoma remote from infarcted brain tissue, 3b: Intraventricular hemorrhage, 3c: Subarachnoid hemorrhage, 3d: Subdural hemorrhage)</p> <p>aspects1: Alberta stroke program early CT score of anterior circulation on CTscan</p> <p>aspect2: Alberta stroke program early CT score of anterior circulation on DWI- Diffusion-weighted Imaging.</p> <p>aspects3: Alberta stroke program early CT score of posterior circulation on CTscan</p> <p>aspects4: Alberta stroke program early CT score of posterior circulation on DWI- Diffusion-weighted Imaging.</p> <p> </p> <p>nihss2: National Institute of Health Stroke Scale before intervention</p> <p>grady: Grady coma scale before intervention</p> <p> </p> <p>rtpa: Use alteplase (0: No, 1: Yes)</p> <p>thromb: Thrombectomy (0: No, 1: Yes)</p> <p>crani: Craniectomy (0: No, 1: Yes).</p> <p>coil: Endovascular coiling (0: No, 1: Yes)</p> <p> </p> <p>mode: Ventilation mode</p> <p>mv: Mechanical ventilation (L/min)</p> <p>fio2: Fraction of inspired oxygen (%)</p> <p>peep: Positive end-expiratory pressure (cmH<sub>2</sub>O)</p> <p>sc: Static compliance (mL/cmH<sub>2</sub>O)</p> <p>alv: Pulmonary consolidation (0: No, 1: ¼ lung, 2: ½ lung, 3: ¾ lung, 4: Complete lung)</p> <p>sf: spo2/fio2 ratio.</p> <p> </p> <p>p13a: Number of pulse beats at time -13 (conventional mechanical ventilation stage)</p> <p>s13a: Systolic blood pressure at time -13 (conventional mechanical ventilation stage)</p> <p>d13a: Diastolic blood pressure at time -13 (conventional mechanical ventilation stage)</p> <p>sp13a: SpO<sub>2</sub> at time -13 (conventional mechanical ventilation stage)</p> <p>e13a: EtCO<sub>2</sub> at time -13 (conventional mechanical ventilation stage)</p> <p> </p> <p>p12a: Number of pulse beats at time -12 (conventional mechanical ventilation stage)</p> <p>s12a: Systolic blood pressure at time -12 (conventional mechanical ventilation stage)</p> <p>d12a: Diastolic blood pressure at time -12 (conventional mechanical ventilation stage)</p> <p>sp12a: SpO<sub>2</sub> at time -12 (conventional mechanical ventilation stage)</p> <p>e12a: EtCO<sub>2</sub> at time -12 (conventional mechanical ventilation stage)</p> <p> </p> <p>p11a: Number of pulse beats at time -11 (conventional mechanical ventilation stage)</p> <p>s11a: Systolic blood pressure at time -11 (conventional mechanical ventilation stage)</p> <p>d11a: Diastolic blood pressure at time -11 (conventional mechanical ventilation stage)</p> <p>sp11a: SpO<sub>2</sub> at time -11 (conventional mechanical ventilation stage)</p> <p>e11a: EtCO<sub>2</sub> at time -11 (conventional mechanical ventilation stage)</p> <p> </p> <p>p10a: Number of pulse beats at time -10 (conventional mechanical ventilation stage)</p> <p>s10a: Systolic blood pressure at time -10 (conventional mechanical ventilation stage)</p> <p>d10a: Diastolic blood pressure at time -10 (conventional mechanical ventilation stage)</p> <p>sp10a: SpO<sub>2</sub> at time -10 (conventional mechanical ventilation stage)</p> <p>e10a: EtCO<sub>2</sub> at time -10 (conventional mechanical ventilation stage)</p> <p> </p> <p>p9a: Number of pulse beats at time -9 (conventional mechanical ventilation stage)</p> <p>s9a: Systolic blood pressure at time -9 (conventional mechanical ventilation stage)</p> <p>d9a: Diastolic blood pressure at time -9 (conventional mechanical ventilation stage)</p> <p>sp9a: SpO<sub>2</sub> at time -9 (conventional mechanical ventilation stage)</p> <p>e9a: EtCO<sub>2</sub> at time -9 (conventional mechanical ventilation stage)</p> <p> </p> <p>p8a: Number of pulse beats at time -8 (conventional mechanical ventilation stage)</p> <p>s8a: Systolic blood pressure at time -8 (conventional mechanical ventilation stage)</p> <p>d8a: Diastolic blood pressure at time -8 (conventional mechanical ventilation stage)</p> <p>sp8a: SpO<sub>2</sub> at time -8 (conventional mechanical ventilation stage)</p> <p>e8a: EtCO<sub>2</sub> at time -8 (conventional mechanical ventilation stage)</p> <p> </p> <p>p7a: Number of pulse beats at time -7 (conventional mechanical ventilation stage)</p> <p>s7a: Systolic blood pressure at time -7 (conventional mechanical ventilation stage)</p> <p>d7a: Diastolic blood pressure at time -7 (conventional mechanical ventilation stage)</p> <p>sp7a: SpO<sub>2</sub> at time -7 (conventional mechanical ventilation stage)</p> <p>e7a: EtCO<sub>2</sub> at time -7 (conventional mechanical ventilation stage)</p> <p> </p> <p>p6a: Number of pulse beats at time -6 (conventional mechanical ventilation stage)</p> <p>s6a: Systolic blood pressure at time -6 (conventional mechanical ventilation stage)</p> <p>d6a: Diastolic blood pressure at time -6 (conventional mechanical ventilation stage)</p> <p>sp6a: SpO<sub>2</sub> at time -6 (conventional mechanical ventilation stage)</p> <p>e6a: EtCO<sub>2</sub> at time -6 (conventional mechanical ventilation stage)</p> <p> </p> <p>p5a: Number of pulse beats at time -5 (conventional mechanical ventilation stage)</p> <p>s5a: Systolic blood pressure at time -5 (conventional mechanical ventilation stage)</p> <p>d5a: Diastolic blood pressure at time -5 (conventional mechanical ventilation stage)</p> <p>sp5a: SpO<sub>2</sub> at time -5 (conventional mechanical ventilation stage)</p> <p>e5a: EtCO<sub>2</sub> at time -5 (conventional mechanical ventilation stage)</p> <p> </p> <p>p4a: Number of pulse beats at time -4 (conventional mechanical ventilation stage)</p> <p>s4a: Systolic blood pressure at time -4 (conventional mechanical ventilation stage)</p> <p>d4a: Diastolic blood pressure at time -4 (conventional mechanical ventilation stage)</p> <p>sp4a: SpO<sub>2</sub> at time -4 (conventional mechanical ventilation stage)</p> <p>e4a: EtCO<sub>2</sub> at time -4 (conventional mechanical ventilation stage)</p> <p> </p> <p>p3a: Number of pulse beats at time -3 (conventional mechanical ventilation stage)</p> <p>s3a: Systolic blood pressure at time -3 (conventional mechanical ventilation stage)</p> <p>d3a: Diastolic blood pressure at time -3 (conventional mechanical ventilation stage)</p> <p>sp3a: SpO<sub>2</sub> at time -3 (conventional mechanical ventilation stage)</p> <p>e3a: EtCO<sub>2</sub> at time -3 (conventional mechanical ventilation stage)</p> <p> </p> <p>p2a: Number of pulse beats at time -2 (conventional mechanical ventilation stage)</p> <p>s2a: Systolic blood pressure at time -2 (conventional mechanical ventilation stage)</p> <p>d2a: Diastolic blood pressure at time -2 (conventional mechanical ventilation stage)</p> <p>sp2a: SpO<sub>2</sub> at time -2 (conventional mechanical ventilation stage)</p> <p>e2a: EtCO<sub>2</sub> at time -2 (conventional mechanical ventilation stage)</p> <p> </p> <p>p1a: Number of pulse beats at time -1 (conventional mechanical ventilation stage)</p> <p>s1a: Systolic blood pressure at time -1 (conventional mechanical ventilation stage)</p> <p>d1a: Diastolic blood pressure at time -1 (conventional mechanical ventilation stage)</p> <p>sp1a: SpO<sub>2</sub> at time -1 (conventional mechanical ventilation stage)</p> <p>e1a: EtCO<sub>2</sub> at time -1 (conventional mechanical ventilation stage)</p> <p> </p> <p>p0a: Number of pulse beats at time 0 (conventional mechanical ventilation stage)</p> <p>s0a: Systolic blood pressure at time 0 (conventional mechanical ventilation stage)</p> <p>d0a: Diastolic blood pressure at time 0 (conventional mechanical ventilation stage)</p> <p>sp0a: SpO<sub>2</sub> at time 0 (conventional mechanical ventilation stage)</p> <p>e0a: EtCO<sub>2</sub> at time 0 (conventional mechanical ventilation stage)</p> <p> </p> <p>p1b: Number of pulse beats at time +1 (advanced Ambu bag system stage)</p> <p>s1b: Systolic blood pressure at time +1 (advanced Ambu bag system stage)</p> <p>d1b: Diastolic blood pressure at time +1 (advanced Ambu bag system stage)</p> <p>sp1b: SpO<sub>2</sub> at time +1 (advanced Ambu bag system stage)</p> <p>e1b: EtCO<sub>2</sub> at time +1 (advanced Ambu bag system stage)</p> <p> </p> <p>p2b: Number of pulse beats at time +2 (advanced Ambu bag system stage)</p> <p>s2b: Systolic blood pressure at time +2 (advanced Ambu bag system stage)</p> <p>d2b: Diastolic blood pressure at time +2 (advanced Ambu bag system stage)</p> <p>sp2b: SpO<sub>2</sub> at time +2 (advanced Ambu bag system stage)</p> <p>e2b: EtCO<sub>2</sub> at time +2 (advanced Ambu bag system stage)</p> <p> </p> <p>p3b: Number of pulse beats at time +3 (advanced Ambu bag system stage)</p> <p>s3b: Systolic blood pressure at time +3 (advanced Ambu bag system stage)</p> <p>d3b: Diastolic blood pressure at time +3 (advanced Ambu bag system stage)</p> <p>sp3b: SpO<sub>2</sub> at time +3 (advanced Ambu bag system stage)</p> <p>e3b: EtCO<sub>2</sub> at time +3 (advanced Ambu bag system stage)</p> <p> </p> <p>p4b: Number of pulse beats at time +4 (advanced Ambu bag system stage)</p> <p>s4b: Systolic blood pressure at time +4 (advanced Ambu bag system stage)</p> <p>d4b: Diastolic blood pressure at time +4 (advanced Ambu bag system stage)</p> <p>sp4b: SpO<sub>2</sub> at time +4 (advanced Ambu bag system stage)</p> <p>e4b: EtCO<sub>2</sub> at time +4 (advanced Ambu bag system stage)</p> <p> </p> <p>p5b: Number of pulse beats at time +5 (advanced Ambu bag system stage)</p> <p>s5b: Systolic blood pressure at time +5 (advanced Ambu bag system stage)</p> <p>d5b: Diastolic blood pressure at time +5 (advanced Ambu bag system stage)</p> <p>sp5b: SpO<sub>2</sub> at time +5 (advanced Ambu bag system stage)</p> <p>e5b: EtCO<sub>2</sub> at time +5 (advanced Ambu bag system stage)</p> <p> </p> <p>p6b: Number of pulse beats at time +6 (advanced Ambu bag system stage)</p> <p>s6b: Systolic blood pressure at time +6 (advanced Ambu bag system stage)</p> <p>d6b: Diastolic blood pressure at time +6 (advanced Ambu bag system stage)</p> <p>sp6b: SpO<sub>2</sub> at time +6 (advanced Ambu bag system stage)</p> <p>e6b: EtCO<sub>2</sub> at time +6 (advanced Ambu bag system stage)</p> <p> </p> <p>p7b: Number of pulse beats at time +7 (advanced Ambu bag system stage)</p> <p>s7b: Systolic blood pressure at time +7 (advanced Ambu bag system stage)</p> <p>d7b: Diastolic blood pressure at time +7 (advanced Ambu bag system stage)</p> <p>sp7b: SpO<sub>2</sub> at time +7 (advanced Ambu bag system stage)</p> <p>e7b: EtCO<sub>2</sub> at time +7 (advanced Ambu bag system stage)</p> <p> </p> <p>p8b: Number of pulse beats at time +8 (advanced Ambu bag system stage)</p> <p>s8b: Systolic blood pressure at time +8 (advanced Ambu bag system stage)</p> <p>d8b: Diastolic blood pressure at time +8 (advanced Ambu bag system stage)</p> <p>sp8b: SpO<sub>2</sub> at time +8 (advanced Ambu bag system stage)</p> <p>e8b: EtCO<sub>2</sub> at time +8 (advanced Ambu bag system stage)</p> <p> </p> <p>p9b: Number of pulse beats at time +9 (advanced Ambu bag system stage)</p> <p>s9b: Systolic blood pressure at time +9 (advanced Ambu bag system stage)</p> <p>d9b: Diastolic blood pressure at time +9 (advanced Ambu bag system stage)</p> <p>sp9b: SpO<sub>2</sub> at time +9 (advanced Ambu bag system stage)</p> <p>e9b: EtCO<sub>2</sub> at time +9 (advanced Ambu bag system stage)</p> <p> </p> <p>p10b: Number of pulse beats at time +10 (advanced Ambu bag system stage)</p> <p>s10b: Systolic blood pressure at time +10 (advanced Ambu bag system stage)</p> <p>d10b: Diastolic blood pressure at time +10 (advanced Ambu bag system stage)</p> <p>sp10b: SpO<sub>2</sub> at time +10 (advanced Ambu bag system stage)</p> <p>e10b: EtCO<sub>2</sub> at time +10 (advanced Ambu bag system stage)</p> <p> </p> <p>p11b: Number of pulse beats at time +11 (advanced Ambu bag system stage)</p> <p>s11b: Systolic blood pressure at time +11 (advanced Ambu bag system stage)</p> <p>d11b: Diastolic blood pressure at time +11 (advanced Ambu bag system stage)</p> <p>sp11b: SpO<sub>2</sub> at time +11 (advanced Ambu bag system stage)</p> <p>e11b: EtCO<sub>2</sub> at time +11 (advanced Ambu bag system stage)</p> <p> </p> <p>p12b: Number of pulse beats at time +12 (advanced Ambu bag system stage)</p> <p>s12b: Systolic blood pressure at time +12 (advanced Ambu bag system stage)</p> <p>d12b: Diastolic blood pressure at time +12 (advanced Ambu bag system stage)</p> <p>sp12b: SpO<sub>2</sub> at time +12 (advanced Ambu bag system stage)</p> <p>e12b: EtCO<sub>2</sub> at time +12 (advanced Ambu bag system stage)</p> <p> </p> <p>p13b: Number of pulse beats at time +13 (advanced Ambu bag system stage)</p> <p>s13b: Systolic blood pressure at time +13 (advanced Ambu bag system stage)</p> <p>d13b: Diastolic blood pressure at time +13 (advanced Ambu bag system stage)</p> <p>sp13b: SpO<sub>2</sub> at time +13 (advanced Ambu bag system stage)</p> <p>e13b: EtCO<sub>2</sub> at time +13 (advanced Ambu bag system stage)</p> <p> </p> <p>p14b: Number of pulse beats at time +14 (advanced Ambu bag system stage)</p> <p>s14b: Systolic blood pressure at time +14 (advanced Ambu bag system stage)</p> <p>d14b: Diastolic blood pressure at time +14 (advanced Ambu bag system stage)</p> <p>sp14b: SpO<sub>2</sub> at time +14 (advanced Ambu bag system stage)</p> <p>e14b: EtCO<sub>2</sub> at time +14 (advanced Ambu bag system stage)</p>
Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer
<p>Wallen ZD, Ko H, Nesline MK, Hastings SB, Strickland KC, Previs RA, Zhang S, Pabla S, Conroy J, Jackson JB, Saini KS, Jensen TJ, Eisenberg M, Caveney B, Sathyan P, Severson EA, Ramkissoon SH. <strong>Real-world comprehensive genomic and immune profiling reveals distinct age- and sex-based genomic and immune landscapes in tumors of patients with non-small cell lung cancer.</strong> <em>Front Immunol.</em> 2024 Jun 21;15:1413956. doi: <a href="https://doi.org/10.3389/fimmu.2024.1413956">10.3389/fimmu.2024.1413956</a>. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38975340/">38975340</a>; PMCID: <a href="https://pmc.ncbi.nlm.nih.gov/articles/PMC11224431/">PMC11224431</a>.</p> <p><strong>ABSTRACT</strong></p> <p>Younger patients with non-small cell lung cancer (NSCLC) (<50 years) represent a significant patient population with distinct clinicopathological features and enriched targetable genomic alterations compared to older patients. However, previous studies of younger NSCLC suffer from inconsistent findings, few studies have incorporated sex into their analyses, and studies targeting age-related differences in the tumor immune microenvironment are lacking. We performed a retrospective analysis of 8,230 patients with NSCLC, comparing genomic alterations and immunogenic markers of younger and older patients while also considering differences between male and female patients. We defined older patients as those ≥65 years and used a 5-year sliding threshold from <45 to <65 years to define various groups of younger patients. Additionally, in an independent cohort of patients with NSCLC, we use our observations to inform testing of the combinatorial effect of age and sex on survival of patients given immunotherapy with or without chemotherapy. We observed distinct genomic and immune microenvironment profiles for tumors of younger patients compared to tumors of older patients. Younger patient tumors were enriched in clinically relevant genomic alterations and had gene expression patterns indicative of reduced immune system activation, which was most evident when analyzing male patients. Further, we found younger male patients treated with immunotherapy alone had significantly worse survival compared to male patients ≥65 years, while the addition of chemotherapy reduced this disparity. Contrarily, we found younger female patients had significantly better survival compared to female patients ≥65 years when treated with immunotherapy plus chemotherapy, while treatment with immunotherapy alone resulted in similar outcomes. These results show the value of comprehensive genomic and immune profiling (CGIP) for informing clinical treatment of younger patients with NSCLC and provides support for broader coverage of CGIP for younger patients with advanced NSCLC.</p> <p><strong>DATA AVAILABILITY: </strong></p> <p>De-identified, individual-level patient data, genomic variants, and individual immune gene expression data used in the manuscript can be found in this repository (https://zenodo.org/record/11396552). An R markdown file with R code used to perform the analyses and generate figures is also provided in the repository along with the data. All versions of software used are provided in the Methods section of the manuscript. Raw sequencing data were derived from routine clinical testing of real-world patients and cannot be shared publicly. Data for immune gene expression signatures are not publicly available due to a non‑provisional patent filing covering the methods used to generate and analyze these data but are available from the corresponding author on reasonable request.</p>
AProtocol for Managing Orthodontic Complications in Patients with Thalassemia and Haemoglobin Disorder; Article Review
<p>Hemoglobinopathies are known as haemoglobin production disorders. Familial disorders caused by thalassemia or sickle cell anaemia are autosomal recessive disorders affecting haemoglobin production and structure. Objectives:This article review aimed to clarify protocols for managing orthodontic complications in patients with thalassemia and haemoglobin disorder. The article explains how to deal with common dental and orthodontic issues that patients with these conditions may experience.It provides guidance on diagnosing and treating these issues to ensure the best possible outcomes for these patients. Conclusion:Hemoglobinopathies can cause dental diseases, which can be particularly concerning for children with this condition. While specialists are responsible for treating dental diseases, prevention is the best approach. Physicians with adequate knowledge of the diseases can address this issue safely and effectively. Paying attention to this matter is essential to ensure the best possible patient outcomes.</p>
MOTU data. FHIR-standardized data collection on the clinical rehabilitation pathway of trans-femoral amputation patients.
<h3>Dataset presented in the article "MOTU on FHIR: A 10-year data collection on the clinical rehabilitation pathway of 1006 trans-femoral amputees".</h3> <p>Data has been anonymised prior the publication. The data are in Comma-separated-values (CSV) format. </p> <p>This work has been conducted within the framework of the MOTU++ project (PR19-PAI-P2).</p> <p><span>This research was co-funded by the Complementary National Plan PNC-I.1 "Research initiatives for innovative technologies and pathways in the health and welfare sector” D.D. 931 of 06/06/2022, DARE - DigitAl lifelong pRevEntion initiative, code PNC0000002, CUP: (B53C22006450001) and by the Italian National Institute for Insurance against Accidents at Work (INAIL) within the MOTU++ project (PR19-PAI-P2). </span></p> <p><span>Authors express their gratitude to all the AlmaHealthDB Team.</span></p>
Dataset from: "Assessment of depression, anxiety, and psychological symptoms in parents of pediatric palliative care patients: A single-center case-control study"
<p>The dataset comprises raw data from a case-control study that compared levels of depression, anxiety, and general psychological symptoms between parents of pediatric palliative care (PPC) patients and parents of healthy controls.</p> <p>Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), and Symptom Checklist-90 Revised (SCL-90-R) were employed to provide a comprehensive and nuanced understanding of the mental health challenges faced by parents.</p> <p>The designation "case" in the first column (A) represents the parents of PPC patients, while the designation "control" represents the control group. The columns labeled B to S present demographic characteristics data, while columns T to AR present inventory scores. Columns BB to GC, in turn, present the responses to the inventory items.</p> <p> </p> <p> </p>
Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
<p>This repository contains CITE-seq data generated from CML stem and progenitor cells before and after hydroxyurea treatment using the BD Rhapsody Single-Cell Analysis System. </p> <p><strong><br>File descriptions:</strong></p> <p>1. RSEC-adjusted UMI count files generated using the BD Rhapsody Targeted Analysis Pipeline (v. 1.10.1):</p> <ul> <li>CartridgeS1_RSEC_MolsPerCell.csv</li> </ul> <p>2. RSEC-adjusted UMI counts for cells remaining after cell quality filtering using SeqGeq software (genes expressed vs library size):</p> <ul> <li>CartridgeS1_RSEC_MolsPerCell_postQC.csv</li> </ul> <p>3. Sample tag (sample of origin) calls for each putative cell, outputted by the BD Rhapsody Targeted Analysis Pipeline (v. 1.10.1). </p> <ul> <li>CartridgeS1_Sample_Tag_Calls.csv</li> </ul> <p> </p>
Fig.3. Relation between depression level expresed Fig.4 in Oxidative Stress Indicators, Depression And Qua Lity Of Live L Evel S In Co Rona Ry Heart Disease Patients
Fig.3. Relation between depression level expresed Fig.4. Box plot displaying the distribution of the in Geriatric depression score points and oxidative data showing differences in Geriatric depression stress parameter (GPx) score points in primary and recurrent SCHD patients according to gender.
Fig.1. Relation between depression level expresed Fig.2 in Oxidative Stress Indicators, Depression And Qua Lity Of Live L Evel S In Co Rona Ry Heart Disease Patients
Fig.1. Relation between depression level expresed Fig.2. Relation between depression level expresed in Geriatric depression score points andlevelof in Geriatric depression score points and oxidative life Quality. stress parameter (MDA).
Differential abundance and gene set enrichment in plasma of cancer patients versus controls
<p>Version update: Human Protein Atlas v23 used for gene set enrichment analysis (instead of Human Protein Atlas v18)</p> <p><br>DESeq2 differential abundance output for genes with q < 0.05 and |log<sub>2</sub> fold change| > 1 in cancer vs control plasma samples:</p> <ul> <li><em>differentialabundance_pancancer.txt</em>: tables with differentially abundant genes (|log2(fold change)|>1 and adjusted p>0.05) per cancer-control comparison (cancertype) in a pan-cancer plasma sample cohort (25 locally advanced to metastatic cancer types - 7 or 8 patients per type - vs 8 cancer-free control donors)</li> <li><em>differentialabundance_threecancer.txt</em>: tables with differentially abundant genes (|log2(fold change)|>1 and adjusted p>0.05) per cancer-control comparison (cancertype) in the three-cancer plasma cohort (ovarian, prostate and uterine cancer - 11 or 12 patients per type - vs 20 cancer-free controls) <ul> <li>Gene_id: Ensembl gene id (GChr38 v91); baseMean: mean of normalized counts for all samples; log2FoldChange: log2 fold change for cancer vs control; lfcSE: standard error for cancer vs control; stat: Wald statistic for cancer vs control; pvalue: Wald test p-value for cancer vs control; padj: Benjamini-Hochberg corrected p-value; cancertype: respective cancer type abbreviation of cancer patient plasma samples that were compared to plasma samples of controls.</li> </ul> </li> </ul> <p>Gene set enrichment analyses based on fold change ranked gene lists (cancer versus control) - results obtained with fgea (v1.22.0):</p> <ul> <li><em>customgenesets.txt</em>: custom gene set lists based on RNA Atlas (&Human Protein Atlas), Tabula Sapiens, GTEX, TCGA data. <ul> <li>Reference: reference to create gene sets (including RNA Atlas, Human Protein Atlas, Tabula Sapiens, GTEX, and TCGA); set: set name; genes: gene list for set</li> </ul> </li> <li><em>GSEA_pancancer.txt</em> & <em>GSEA_threecancer.txt</em>: gene set enrichment results based on fold change ranked gene list (specific cancer type versus controls) in pan-cancer cohort and three-cancer cohort, respectively <ul> <li>Sets: gene set category (HALLMARK and KEGG: Hallmark and Canonical Pathways gene sets obtained from MSigDB (v2022.1); CUSTOM: custom tissue and cell type specific gene sets as defined in <em>customgenesets.txt)</em>; pathway: pathway/set name; pval: enrichment p-value; padj: Benjamini-Hochberg adjusted p-value; log2err: expected error for the standard deviation of the P-value logarithm; ES: enrichment score, same as in Broad GSEA implementation; NES: enrichment score normalized to mean enrichment of random samples of the same size; size: size of the pathway after removing genes without statistic values; leadingEdge: leading edge genes that drive the enrichment; Disease: respective cancer type abbreviation of cancer patient plasma samples that were compared to plasma samples of controls</li> </ul> </li> </ul>
Association between Dysregulated Expression of Ca2+ and ROS-Related Gene Pairs and Breast Cancer Patient Survival
<p>This file is composed of two documents:</p> <ul> <li>Supplementary File 1 containing three Excel files with cumulative proportion survival from redox-related genes, calcium-related genes, and redox and calcium-related genes.</li> <li>Supplementary Table 3 including an Excel file with a functional enrichment analysis using redox and calcium correlated genes. Cell cycle regulation (sheet 1) and Cell adhesion and projection (sheet 2) were the biological processes more enriched.</li> </ul> <p>Both supplementary tables belongs to the study <strong>Association between Dysregulated Expression of Ca2+ and ROS-Related Gene Pairs and Breast Cancer Patient Survival</strong>, published in <strong>Molecular Diagnosis and therapy</strong></p>
Analysing the intra and interregional components of spatial accessibility gravity model to capture the level of equity in the distribution of hospital services: does they influence patient mobility?
<p>aggregated_data_age55+.csv and distance_matrix_age55+.csv have been included in the second version of the dataset as the reference population is limited to resident with 55 years old or more.</p>
Unveiling Pathophysiological Insights: Serum Metabolic Dysregulation in Acute Respiratory Distress Syndrome Patients with Acute Kidney Injury
<p>The uploaded data is an Excel sheet obtained after performing the binning of 1H CPMG NMR spectra acquired using 800 MHz NMR on the serum samples of ARDS patients and ARDS with AKI patients. </p>
BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major Depression -Figure 4. Histogram age distributions of the 100 Schizophrenia patients illustrating clusters of patients at 20, 30, 40, and 50 years old.
<p>The figure below is a histogram distribution of the ages of one hundred Schizophrenia<br> patients in this study. There appears to be a cyclical peak every ten-years cycles at 20, 30, 40, and<br> 50-year-old patients. This may suggest a recent finding that CD8 T cells, which play a pivotal role<br> in mediating long-term immunity to Toxoplasma, are down-regulated in schizophrenia patients<br> (Bhadra et al., 2013). Based on the aforementioned statements, a vaccine for Toxoplasmosis may be<br> difficult to achieve, but the treatment and screening possibilities in patients with psychosis are<br> available today.</p>
BRAIN Journal-Isolating the Norepinephrine Pathway Comparing Lithium in Bipolar Patients to SSRIs in Depressive Patients-Figure 2. Resting state neuroimaging findings illustrating the action of Lithium following whole brain
<p>The axial, saggital, and coronal MRI activation maps illustrate increased delta frequency band neuronal activity in the 46 patients<br> diagnosed with Bipolar Affective Disorder compared to 32 female patients diagnosed with Major Depressive Disorder of Depressive<br> Episode. The Yellow/Orange shades indicate increased neuronal activity in the right Superior Frontal Gyrus (t=0.920, p=0.05060,<br> BA 6, MNI X=20, Y=0, Z=70) and in the right Cingulate Gyrus (t=0.0846, BA 24, MNI X= 5, Y=0, Z=51). Structural anatomy is<br> shown in grey scale (A – anterior; S – superior; P – posterior; L – left; R – right).</p>
BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major Depression -Figure 3. Resulting comparisons isolating the Dopamine D2 Mesolimbic Pathway
<p>Moreover, a study in Prague identified that Toxoplasmosis triggers schizophrenia in<br> predisposed subjects (Flegr et al., 2014). It may very well be that the Toxoplasmosis parasite<br> increasing dopamine secretions in the frontal lobes may very well lead to decreased cerebral<br> volumes. Cat feces, sexual contact, and eating raw or undercooked pork are well known transmitters<br> of the Toxoplasmosis parasite and may be advisable that patients take precautions of the possibility<br> of these triggering symptoms of psychosis with these possible routes of infection. Another adjunct to Atypical Antipsychotics may be to treat the potential cerebral Toxoplasmosis infection with<br> Cotrimoxazole or Pyrimethamine/Clindamycin.</p>
BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major Depression -Figure 2. Resting State neuroimaging findings illustrating the action of atypical antipsychotics on postsynaptic dopamine D2
<p>Contrastingly, the results of the one-hundred males and females diagnosed with<br> Schizophrenia compared to the thirty-two females diagnosed with Major Depressive Disorder or<br> Depressive Episodes. The one-hundred male and female Schizophrenia patients had an average age<br> of 32-years-old and a Standard Deviation of 11.8-years. Whereas, the Depressive Episode and<br> Major Depressive Disorder females had an average age of 50-years old and a Standard Deviation of<br> 11.7-years. The statistically significant neuroimaging results identified the Delta (1.5–6 Hz)<br> frequency band at the neuroanatomical location of the region of the Superior Frontal Gyrus<br> (p=0.007; t=2.08, BA 10, X=25, Y=55, Z=30) with greater neuronal oscillations and synchrony in<br> the one-hundred males and females diagnosed with Schizophrenia than the thirty-two females<br> diagnosed with Depressive Episodes and Major Depressive Disorder.</p>
BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 12 Anorexia Nervosa Patients to 12 Controls-Figure 2: All axial slices of sLORETA imaging results of Resting State EEG Supra-Threshold Voxels in both the Parahippocampal (limbic) and Fusiform (temporal) Gyri illustrating decreased neuronal activity in the Anorexia Nervosa patients.
<p>Results from the sLORETA imaging indicates decreased neuronal activation within the Left<br> Fusiform Gyrus located in the Temporal lobe and Parrahippocampal gyrus, which is located in the<br> Limbic Lobe (Table 1). This correlates with other fMRI findings where patients with early onset<br> AN have exhibited reduced unilateral blood flow in the temporal lobe. The Parahippocampal and<br> Fusiform Gyri are centers that process emotions. Previous studies in which these regions have<br> shown activation involve women that have distorted perceptions of their bodies from a cognitive<br> perspective (Santel et al., 2006). It is apparent from our findings that the Fusiform Gyrus may play<br> a vital role in the processing of visual appearance of the human body. There is also a correlation<br> with the somatosensory limbic pathway in the limbic lobe, due to the similarity of function.</p>
BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 100 Schizophrenia Patients to 48 Patients with Major Depression -Figure 1. Group comparisons designed for isolating the mesolimbic Dopamine D2
<p>All patients diagnosed with Schizophrenia were medicated with atypical antipsychotics, Olanzapine (dose 5mg/day to 20mg/day) or Risperidone (dose 1mg/day to 4mg/day) blocking both Dopamine D2 and Serotonin 5-HT2 receptors. Whereas, all of the patients diagnosed with Major Depression or Depressive Episode were medicated with Sertraline (50mg/day to 200mg/day maximum dose) or Citalopram (20mg/day to 40mg/day maximum dose). This research protocol was approved by the Bioethical Commission of the Medical University of Lublin. </p>
BRAIN Journal-Electrophysiological Neuroimaging using sLORETA Comparing 12 Anorexia Nervosa Patients to 12 Controls-Figure 1: sLORETA imaging results of Resting State EEG Supra-Threshold Voxels in both the Parahippocampal (limbic) and Fusiform (temporal) Gyri illustrating decreased neuronal activity in the Anorexia Nervosa patients relative to Control participants
<p>The findings of the sLORETA analysis indicated that, the difference is statistically<br> significant (p=0.03) using a one-tailed t-test: Anorexia > Controls. The brains of the patients with<br> Anorexia Nervosa illustrated decreased neuronal activity in the Left Fusiform Gyrus and the Left<br> Parahippocampal Gyrus (p=0.03) in the resting-state brains when Anorexia Patients were sitting for<br> 3min, as compared to the Controls sitting for 3minutes.</p>
BRAIN Journal-Isolating the Norepinephrine Pathway Comparing Lithium in Bipolar Patients to SSRIs in Depressive Patients-Figure 1. Resting state neuroimaging findings illustrating the action of Lithium following whole brain
<p>The axial, saggital, and coronal MRI activation maps illustrate neuronal activity of 46 patients diagnosed with Bipolar Affective<br> Disorder compared to 16 male patients diagnosed with Major Depressive Disorder of Depressive Episode. The Yellow/Orange<br> shades indicate increased neuronal activity in the right Superior Temporal Gyrus (t=1.403, p=0.00780, BA 41, MNI X=45, Y= -35,<br> Z=10) with activation also in the Fusiform Gyrus (t=1.26, BA 20, MNI X= 45, Y= -35, Z=10), the Parahippocampal Gyrus (t=1.29,<br> BA 36, MNI X=45, Y= -35, Z=10). (b) Increased neuronal activity in the Cingulate Gyrus (t=1.06, BA 32, MNI X=45, Y= -35,<br> Z=10). Structural anatomy is shown in grey scale (A – anterior; S – superior; P – posterior; L – left; R – right).</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.